KarXT Schizophrenia Win; CBD for Anxiety; No Nuplazid for Alzheimer's Psychosis

— News and commentary from the psychiatry world

MedicalToday
Illustration of a brain shaped maze.

The met its primary endpoint achieving a significant reduction in PANSS total score with oral KarXT (xanomeline-trospium) versus placebo in people with schizophrenia, Karuna Therapeutics announced.

As many as 87% of may not be receiving life-saving medications like methadone, buprenorphine, and naltrexone. (International Journal of Drug Policy)

After 12 weeks, youth with had an average 42.6% drop in symptom severity. "The young people had fewer panic attacks and could do things which they were previously unable to do," said Paul Amminger, MD, PhD, of Orygen in Australia. (Journal of Clinical Psychiatry)

Children of individuals with Alzheimer's often of their own diagnosis one day. (New York Times)

Following a negative review from an advisory panel earlier this year, the for an additional indication for treatment of hallucinations and delusions associated with Alzheimer's disease psychosis, Acadia Pharmaceuticals said.

Kids with had a much higher risk for developing neuropsychiatric conditions, according to the U.K-based IMAGINE study. (The Lancet Psychiatry)

Older Americans are still feeling the mental burden from the . (The Hill)

A Mendelian randomization study found global cortical thickness could be used to and binge drinking behaviors. (JAMA Psychiatry)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.